Mallinckrodt - MCKPF STOCK NEWS

Welcome to our dedicated page for Mallinckrodt news (Ticker: mckpf), a resource for investors and traders seeking the latest updates and insights on Mallinckrodt stock.

Mallinckrodt PB Ltd Co, also known as MCKPF, is a global specialty pharmaceutical company focused on developing, manufacturing, and distributing specialty pharmaceutical products and therapies. They operate in the areas of autoimmune and rare diseases, neurology, rheumatology, hepatology, and more. Mallinckrodt recently announced FDA approval for their Acthar® Gel Single-Dose Pre-filled SelfJect™ Injector, a new delivery device designed to help patients with chronic and acute inflammatory and autoimmune conditions administer Acthar Gel subcutaneously. With a track record spanning over 70 years and a commitment to patients, Mallinckrodt continues to provide innovative therapies and support programs.

03/26/2024 04:01 PM

News

Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance

Rhea-AI Summary

Mallinckrodt plc reports strong financial results for fiscal year 2023, exceeding high-end guidance on net sales and adjusted EBITDA. Key milestones achieved in Specialty Brands with successful product launches and FDA approvals. New board members appointed. Financial guidance for 2024 provided. Detailed analysis of positive and negative aspects.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/11/2024 06:52 AM

News

Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients

Rhea-AI Summary

Mallinckrodt plc announces positive findings from a retrospective analysis on Acthar Gel treatment outcomes for African American and non-African American patients with symptomatic sarcoidosis. The study indicates similar health status improvement and symptom reduction in both groups, suggesting Acthar Gel as a viable treatment option for sarcoidosis patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/04/2024 06:45 AM

News

Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands

Rhea-AI Summary

Mallinckrodt plc appoints Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands. Mr. O'Neill brings over 25 years of experience in manufacturing operations and will lead key initiatives to enhance supply performance and launch new products. Mallinckrodt aims for long-term growth under his leadership.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/01/2024 08:50 AM

News

Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

Rhea-AI Summary

Mallinckrodt plc receives FDA approval for Acthar Gel Single-Dose Pre-filled SelfJect Injector, a new delivery device for patients with inflammatory and autoimmune conditions. The device aims to simplify Acthar Gel administration, enhancing patient control. The product is set to launch in the U.S. in the second half of 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is Mallinckrodt PB Ltd Co focused on?

Mallinckrodt PB Ltd Co is focused on developing, manufacturing, and distributing specialty pharmaceutical products and therapies.

What recent achievement did Mallinckrodt have?

Mallinckrodt recently announced FDA approval for their Acthar® Gel Single-Dose Pre-filled SelfJect™ Injector, a new delivery device designed for patients with chronic and acute inflammatory and autoimmune conditions.

What areas does Mallinckrodt operate in?

Mallinckrodt operates in the areas of autoimmune and rare diseases, neurology, rheumatology, hepatology, and more.

What support programs does Mallinckrodt offer?

Mallinckrodt offers a suite of services for eligible patients, including support with insurance coverage, commercial copay assistance, a patient assistance program, injection training services, and customized assistance by a nurse navigator.